We stained CD177 as a neutrophil surface molecule that is stably expressed in neutrophils independent of gender, age or activation state, making it a reliable marker for tumour-infiltrating neutrophils in the circulation, e.g., from the primary tumour site to metastatic lesions.17 Here we identified CD177-positive neutrophil infiltration as a predictor of adverse clinical response to bevacizumab treatment. Here, CD177 is linked to neoplasm.